Diabetic kidney disease is rising in India significantly

Diabetic kidney disease is increasing in India, affecting 25-30% of people with diabetes. Early detection is crucial to prevent kidney failure, with the Urinary Albumin-to-Creatinine Ratio (UACR) being a key marker for identifying early damage. Sodium-glucose cotransporter-2 (SGLT2) inhibitors, such as empagliflozin and dapagliflozin, are now recognized for their effectiveness in managing both diabetes and chronic kidney disease (CKD). These medications help reduce albumin levels, preserve kidney function, and lower cardiovascular risks. Experts emphasize the importance of early screening and treatment to slow the progression of kidney disease in diabetic patients. The use of SGLT2 inhibitors represents a significant advancement in improving patient outcomes and quality of life.